Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Dexcom, Inc., San Diego, California, USA.
Diabetes Technol Ther. 2024 Jun;26(6):394-402. doi: 10.1089/dia.2023.0513. Epub 2024 Apr 26.
We used continuous glucose monitoring (CGM) data to investigate glycemic outcomes in a real-world population with type 1 diabetes (T1D) from South Korea, where the widespread use of CGM and the nationwide education program began almost simultaneously. Data from Dexcom G6 users with T1D in South Korea were collected between January 2019 and January 2023. Users were included if they provided at least 90 days of glucose data and used CGM at least 70% of the days in the investigational period. The relationship between CGM utilization and glycemic metrics, including the percentage of time in range (TIR), time below range (TBR), and time above range (TAR), was assessed. The study was approved by the Institutional Review Board of Samsung Medical Center (SMC 2023-05-030). A total of 2288 users were included. Mean age was 41.5 years (57% female), with average uploads of 428 days. Mean TIR was 62.4% ± 18.5%, mean TBR <70 mg/dL was 2.6% ± 2.8%, mean TAR >180 mg/dL was 35.0% ± 19.3%, mean glucose was 168.1 ± 35.8 mg/dL, mean glucose management indicator was 7.2% ± 0.9%, and mean coefficient of variation was 36.7% ± 6.0%. Users with higher CGM utilization had higher TIR (67.8% vs. 52.7%), and lower TBR <70 mg/dL (2.3% vs. 4.7%) and TAR >180 mg/dL (30.0% vs. 42.6%) than those with low CGM utilization ( < 0.001 for all). Users whose data were shared with others had higher TIR than those who did not (63.3% vs. 60.8%, = 0.001). In this South Korean population, higher CGM utilization was associated with a favorably higher mean TIR, which was close to the internationally recommended target. Using its remote data-sharing feature showed beneficial impact on TIR.
我们使用连续血糖监测（CGM）数据来研究韩国真实世界 1 型糖尿病（T1D）人群的血糖结局，韩国广泛使用 CGM 和全国性教育计划几乎同时开始。收集了韩国 Dexcom G6 使用者的 T1D 数据，时间为 2019 年 1 月至 2023 年 1 月。如果患者提供至少 90 天的血糖数据且在研究期间至少有 70%的天数使用 CGM，则将其纳入研究。评估了 CGM 使用率与血糖指标（包括时间在目标范围内（TIR）、时间低于目标范围（TBR）和时间高于目标范围（TAR）的百分比）之间的关系。该研究获得了三星医疗中心机构审查委员会的批准（SMC 2023-05-030）。共纳入 2288 名患者。平均年龄为 41.5 岁（57%为女性），平均上传天数为 428 天。平均 TIR 为 62.4%±18.5%，平均 TBR <70mg/dL 为 2.6%±2.8%，平均 TAR >180mg/dL 为 35.0%±19.3%，平均血糖为 168.1±35.8mg/dL，平均血糖管理指标为 7.2%±0.9%，平均变异系数为 36.7%±6.0%。CGM 使用频率较高的患者 TIR 较高（67.8% vs. 52.7%），TBR <70mg/dL（2.3% vs. 4.7%）和 TAR >180mg/dL（30.0% vs. 42.6%）较低（均<0.001）。与不分享数据的患者相比，数据被他人分享的患者 TIR 更高（63.3% vs. 60.8%，=0.001）。在韩国人群中，CGM 使用率越高，平均 TIR 越高，接近国际推荐目标。使用其远程数据共享功能对 TIR 有有益影响。
